Case Study: Eli Lilly accelerates clinical trial design with Linguamatics NLP

The Linguamatics NLP platform enabled Eli Lilly and Company to assist in the design of new clinical trials and increase speed to business insight

Eli Lilly and Company faced a challenge in accelerating the design of its clinical trials. Manually extracting and synthesizing key data from vast clinical trial databases was a slow, labor-intensive, and error-prone process that hindered their ability to analyze the competitive landscape. To find a scalable solution, they turned to the natural language processing (NLP) platform from vendor Linguamatics.

Linguamatics implemented its NLP-based text mining solution to automatically identify, interpret, and extract key facts into a structured format from unstructured trial data. This provided Eli Lilly with precise, semantically normalized data, enabling faster and more accurate insights. The results included a massive reduction in manual effort, the elimination of errors from manual data entry, and significant cost savings. Ultimately, the solution expedited clinical trial design, contributing to a faster time to market for new drugs.

Eli Lilly and Company

Eric Su

Principal Research Scientist